Zacks
  • Home
  • Analyst Bios
  • Research Reports
    • Companies by Analyst
      • Biotech - David Bautz, PhD
      • Biotech - John Vandermosten, CFA
      • Bank & Finance – Ann Heffron, CFA, CPA
      • Special Situations – Ian Gilson, PhD, CFA
      • Special Situations – Steven Ralston, CFA
      • Med-Tech – Brian Marckx, CFA
      • Med-Tech - Anita Dushyanth, PhD
      • Technology – Lisa Thompson
      • Technology - M. Marin
      • Healthcare - Beth Senko, CFA
    • Companies by Name
  • Distribution
    • Institutional Distribution
    • Retail Distribution
    • Social Media
    • RSS Feeds
  • Our Partners
    • IR Firms
  • Contact
  • Subscribe
    • Zacks SCR Premium
    • Zacks SCR On-Call
David Bautz, PhD, Senior Biotechnology Analyst

David Bautz joined Zacks as a Biotechnology Analyst in February 2014. Prior to joining Zacks, David was an NRSA postdoctoral fellow investigating the genetics of colorectal cancer morphology. During his tenure as a postdoctoral fellow David also conducted research developing active immunotherapies and monoclonal antibodies as potential treatments for colorectal cancer.



David obtained his PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill in 2008. His dissertation research focused on the characterization of autoantibodies in patients suffering from an orphan autoimmune disease.



Prior to obtaining his PhD, David worked for two years as a research associate at Human Genome Sciences, Inc., a biotechnology company that was eventually acquired by GlaxoSmithKline.



David obtained his BS and MS degrees in Biochemistry from Virginia Tech.


Follow @DavidBautz

David Bautz's Universe Includes










































Latest

Notes in the Press

December 10, 2019 MBII: Marrone Bio Innovations reports results of nematode control on corn and improved stress tolerance on barley and wheat.
December 9, 2019 DARE: Our Take On Ovaprene PCT Data, BV-1 Pivotal Study Design and Microchips Acquisition
December 6, 2019 BTAI: Pivotal Phase 3 Trials for BXCL501 to Initiate by End of 2019…
December 5, 2019 DYAI: Glycosylation Milestone Opens Doors For mAb Production
December 5, 2019 SNGX: CTCL Phase 3 Trial Fully Enrolled; Data in 1Q20…
December 4, 2019 BVXV: Cohort 2 of Pivotal Phase 3 Universal Influenza Vaccine Trial Fully Enrolled…
December 4, 2019 ATE.V: Topline Data for Phase 2b Efficacy Trial of ATB-346 in 1Q20…
December 3, 2019 PMN.TO: A Pole Position in Neurodegenerative Disease
December 2, 2019 OGEN: AG013 Phase 2 Trial Enrollment Complete…
December 2, 2019 MDNA.TO: Updated MDNA55 P2b Data Continues to Exceed Currently Available rGBM Therapies…
 

Invalid login, please try again. You have retries remaining before your account will be locked.

Your account is locked and it will be unlocked automatically in minutes.

User ID:
Password:
Remember my ID:

COPYRIGHT © ZACKS INVESTMENT RESEARCH 2018
  • Disclaimer
  • Privacy Policy
  • Site Map
Tweet Follow @ZacksSmallCap
Powered By Q4 Inc. 5.24.1.3